Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex

被引：55

作者：

Tomioka, H ^{[1
]}

Sato, K

Akaki, T

Kajitani, H

Kawahara, S

Sakatani, M

机构：

[1] Shimane Med Univ, Dept Microbiol & Immunol, Izumo, Shimane 6938501, Japan

[2] Shimane Med Univ, Dept Dermatol, Izumo, Shimane 6938501, Japan

[3] Natl Sanatorium Minami Okayama Hosp, Okayama 7100304, Japan

[4] Natl Sanatorium Kinki Chuo Hosp, Osaka 5918555, Japan

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 1999年 / 43卷 / 12期

关键词：

D O I：

10.1128/AAC.43.12.3001

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We compared the in vitro antimycobacterial activity of a new fluoroquinolone, HSR-903, with strong activity against gram-positive cocci with those of levofloxacin (LVFX), sitafloxacin (STFX), and gatifloxacin (GFLX). The MICs of the quinolones for Mycobacterium tuberculosis and Mycobacterium avium complex were in the order STFX approximate to GFLX < LVFX less than or equal to HSR-903 and STFX less than or equal to GFLX less than or equal to HSR-903 less than or equal to LVFX, respectively. HSR-903 effectively eliminated intramacrophagial M. tuberculosis, as did LVFX, and exhibited bacteriostatic effects against M. tuberculosis replicating in type II alveolar cells.

引用

页码：3001 / 3004

页数：4

共 28 条

[1] The clinical use of fluoroquinolones for the treatment of mycobacterial diseases [J].

Alangaden, GJ ;

Lerner, SA .

CLINICAL INFECTIOUS DISEASES, 1997, 25 (05) :1213-1221

[2] Mycobacterium tuberculosis invades and replicates within type II alveolar cells [J].

Bermudez, LE ;

Goodman, J .

INFECTION AND IMMUNITY, 1996, 64 (04) :1400-1406

[3] Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers [J].

Chien, SC ;

Wong, FA ;

Fowler, CL ;

Callery-D'Amico, SV ;

Williams, RR ;

Nayak, R ;

Chow, AT .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (04) :885-888

[4] Epidemiology of infection by nontuberculous mycobacteria [J].

Falkinham, JO .

CLINICAL MICROBIOLOGY REVIEWS, 1996, 9 (02) :177-+

[5] IN-VITRO ACTIVITIES OF QUINOLONES AGAINST MYCOBACTERIA [J].

GARCIARODRIGUEZ, JA ;

GARCIA, ACG .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 32 (06) :797-808

[6]

Grassi C, 1997, Expert Opin Investig Drugs, V6, P1211, DOI 10.1517/13543784.6.9.1211

[7] Tuberculosis into the next century - Proceedings of a symposium held on 4 February 1995 at the Liverpool School of Tropical Medicine [J].

Hart, CA ;

Beeching, NJ ;

Duerden, BI .

JOURNAL OF MEDICAL MICROBIOLOGY, 1996, 44 (01) :1-+

[8] In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis [J].

Hoffner, SE ;

Gezelius, L ;

Olsson-Liljequist, B .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (06) :885-888

[9] IN-VITRO AND IN-VIVO ACTIVITIES OF LEVOFLOXACIN AGAINST MYCOBACTERIUM-TUBERCULOSIS [J].

JI, BH ;

LOUNIS, N ;

TRUFFOTPERNOT, C ;

GROSSET, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (06) :1341-1344

[10]

Kent P. T., 1985, PUBLIC HLTH MYCOBACT

← 1 2 3 →